Stay updated on Pembrolizumab in Recurrent Gastric Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Recurrent Gastric Cancer Clinical Trial page.

Latest updates to the Pembrolizumab in Recurrent Gastric Cancer Clinical Trial page
- Check3 days agoNo Change Detected
- Check11 days agoChange DetectedThe page now renders a 403 Forbidden error instead of the study record. This makes the study details and navigation inaccessible to users.SummaryDifference21%

- Check18 days agoNo Change Detected
- Check32 days agoChange DetectedThe study record adds a U.S. NIH grant/contract funding line, and the page footer updates to Revision: v3.6.6, indicating a minor version update.SummaryDifference0.1%

- Check53 days agoChange DetectedThe page’s revision is updated to v3.6.5 from v3.6.4, indicating a minor internal update to the page.SummaryDifference0.0%

- Check67 days agoChange DetectedThe page revision was updated from v3.6.3 to v3.6.4, indicating a new deployment of the site. This update does not reflect a substantive change to the study details or content on the page.SummaryDifference0.0%

- Check89 days agoChange DetectedThe page's revision tag was updated from v3.6.2 to v3.6.3. This indicates a new release of the page content.SummaryDifference0.0%

- Check96 days agoChange DetectedThe page's revision label updated from v3.6.0 to v3.6.2, indicating a newer version of the page template. This update does not alter any study content, eligibility criteria, or results.SummaryDifference0.0%

Stay in the know with updates to Pembrolizumab in Recurrent Gastric Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Recurrent Gastric Cancer Clinical Trial page.